Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief Appointment

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the 13 hot stocks to buy with the highest upside potential. As of February 13, nearly 90% of analysts who cover the stock have assigned a Buy or equivalent rating. The consensus 1-year median price target of $73 implies a 76% upside.

Earlier, on January 28, Vera Therapeutics Inc. (NASDAQ:VERA) appointed Matt Skelton as Chief Commercial Officer, who previously served as the executive vice president of the company’s commercial department.

Meanwhile, on January 27, JPMorgan reiterated its Overweight rating and $96 price target on Vera Therapeutics Inc. (NASDAQ:VERA), noting that as competitive readouts emerge in the space, the company’s shares could gradually move higher toward a more appropriate probability-adjusted level. The firm also thinks that atacicept, Vera’s lead drug candidate, is well-positioned in the IgA nephropathy (IgAN) B-Cell modulator space.

On January 16, Cantor Fitzgerald maintained its Overweight rating and $100 price target on the company, expressing confidence in the company’s regulatory prospects and commercial preparations. According to the analyst, all the pieces are in place for a successful regulatory outcome for atacicept’s potential approval for treating IgA nephropathy.

Vera Therapeutics Inc. (NASDAQ:VERA) is a clinical-stage biotech company developing and commercializing transformative treatments for immunological diseases.